A fast, cost-effective breath analysis technology for Helicobacter pYlori screening at both large and small scale.

Informations projet

HYscreen

N° de convention de subvention: 672123

DOI

10.3030/672123

Projet clôturé

Date de signature de la CE 23 Avril 2015

Date de début 1 Mai 2015

Date de fin 31 Octobre 2015

Financé au titre de

• SOCIETAL CHALLENGES - Health, demographic change and well-being

Coût total

€ 71 429,00

Contribution de l’UE

€ 50 000,00

Coordonné par

Bedfont Scientific Limited
United Kingdom

Periodic Reporting for period 1 - HYscreen (A fast, cost-effective breath analysis technology for Helicobacter pYlori screening at both large and small scale.)

Période du rapport: 2015-05-01 au 2015-10-31

Résumé du contexte et des objectifs généraux du projet

HYscreen is a new technology that offers a fast, simple and cost-effective way for Helicobacter pYlori screening, via breath analysis, at both a large and small scale.
Helicobacter (H.) pylori infection has a high prevalence worldwide and close links to gastric cancers (Forman, 2000), gastric lymphoma (Kim et al., 2011), duodenal and gastric ulceration (Hojsak, 2016). Treatment of the infection is of increasing importance creating the need for a widely available H. pylori diagnostics product. Current methods of detection have many limitations from high cost and invasive procedure.
Bedfont Scientific’s solution is via measuring compounds on the breath which can perform the initial diagnosis and confirm if the bacteria has been eradicated. Bedfont is an established business with several breath analysis product ranges and have a wealth of expertise in this specialist market area.
The phase 1 feasibility study has been completed which looked at the development of the prototype and establishing the route to market through research and development and market research. In phase 2 will see the completion of the development of the prototype to final product and preparation for the launch to market.

Travail effectué depuis le début du projet jusqu’à la fin de la période considérée dans le rapport et principaux résultats atteints jusqu’à présent

The feasibility study was completed for the Bedfont Scientific’s HYscreen project. The work performed and main results achieved during the reporting period includes; working on the prototypes to redesign the casing. Bedfont investigated the feasibility of gaining a pharmaceutical license and providing a new diagnostic agent alongside the HYscreen monitor. Another main area of work performed was completing the freedom to operate survey and creating an IP protection strategy highlighting the areas of novelty surrounding our technology needing IP protection.

Progrès au-delà de l’état des connaissances et impact potentiel prévu (y compris l’impact socio-économique et les conséquences sociétales plus larges du projet jusqu’à présent)

The expected result is bringing a final product to market creating high business growth for Bedfont Scientific through increased sales via our global network of distributors. The socio-economic impact that this project will have is creating jobs directly and indirectly. Directly in-house we will need to employ extra staff to cope with sales, marketing, technical and customer service demand. This will be extended to our distributors and beneficiaries who will also need to strengthen their workforce deal with increased demand.
The wider societal impact of the new monitor which detects H. pylori, potentially lowering the cases of gastric conditions related to H. pylori infection including gastric cancers. In a study by Gibert and Calvet (2009) they found that 92% of the patient cohort with gastric ulcers test positive for the H. pylori bacteria. Meaning there is potentially a lot of lives improved with the diagnosis and subsequent treatment of H. pylori.

HYscreen Monitor Concept